Exclusive-TPG explores $5 billion sale of healthcare software company Lyric, sources say
TPG logo is seen in this illustration taken, August 3, 2026. REUTERS/Dado Ruvic/Illustration
Read a summary of this article on FAST.
Get bite-sized news via a new
cards interface. Give it a try.
Click here to return to FAST
Tap here to return to FAST
FAST
NEW YORK, Sept 9 : Private equity firm TPG is exploring the sale of Lyric, in a process that could value the software company which supports payments in the healthcare industry at about $5 billion, people close to the discussions said.
The move comes as software dealmaking has shown signs of recovery after concerns about artificial intelligence disruption triggered a selloff across the software sector earlier this year.
As activity picks up, there remains wariness about what businesses are worth, and to what extent even highly specialized software providers could be affected by the technology’s rapid evolution.
Insurers such as UnitedHealth, CVS and Humana hire Lyric to identify and prevent inaccurate medical claims payments.
![]()
Guess Word
Crack the word, one row at a time
![]()
Buzzword
Create words using the given letters
![]()
Mini Sudoku
Tiny puzzle, mighty brain teaser
![]()
Mini Crossword
Small grid, big challenge
![]()
Word Search
Spot as many words as you can
TPG is working with investment bankers at JPMorgan Chase on a possible sale of Lyric, said the sources, who cautioned that there is no guarantee that the sale process will lead to a deal for Lyric, and also spoke on condition of anonymity to discuss private deliberations.
The company generates about $250 million of annual earnings before interest, taxes, depreciation and amortization, or EBITDA, which normally could put it at a valuation of $5 billion considering a 20 times multiple, the people said.
TPG and JPMorgan declined comment. Lyric didn’t immediately respond to a comment request.
AI DISRUPTION
TPG acquired ClaimsXten for about $2.2 billion in 2022. The business had been part of Change Healthcare, but was sold to help smooth potential antitrust hurdles which threatened to derail Change’s $13 billion acquisition by UnitedHealth. TPG rebranded the company as Lyric the following year.
The investment firm has previously said that, since then, the company has experienced a significant acceleration in revenue growth. While the size of the growth is undisclosed, TPG said Lyric had benefited from the deployment of AI, and its dataset-rich business would compound those benefits.
Despite this, some prospective software-company buyers are assessing whether AI-native competitors could ultimately perform many of the same functions more cheaply. This could undermine the financial assumptions used to value companies, including payment-integrity and claims-management technology firms, the sources said.
Reflecting uncertainties in the space, the stock of smaller public peer Claritev tumbled 80 per cent between September 2025 and May this year as investors fretted about AI disruption to software companies. While it has recovered since then, it is still trading below $38 per share, from $72 per share one year ago.
Source: Reuters
Sign up for our newsletters

Get the CNA app
Stay updated with notifications for breaking news and our best stories
Get WhatsApp alerts
Join our channel for the top reads for the day on your preferred chat app

Get bite-sized news via a new
cards interface. Give it a try.
Click here to return to FAST
Tap here to return to FAST
FAST














